Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara

Meisinger-Henschel C, Schmidt M, Lukassen S, Linke B, Krause L, Konietzny S, Goesmann A, Howley P, Chaplin P, Suter M, Hausmann J (2007)
JOURNAL OF GENERAL VIROLOGY 88(12): 3249-3259.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
DOI
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ; ; ; ; ; ;
Einrichtung
Centrum für Biotechnologie
Centrum für Biotechnologie > Research Group A. Goesmann
Centrum für Biotechnologie > Technologieplattformen > Bioinformatics Resource Facility
Technische Fakultät > Computational Genomics
Technische Fakultät > AG Genominformatik
Centrum für Biotechnologie > Institut für Bioinformatik
Erscheinungsjahr
2007
Zeitschriftentitel
JOURNAL OF GENERAL VIROLOGY
Band
88
Zeitschriftennummer
12
Seite
3249-3259
ISSN
0022-1317
eISSN
1465-2099
PUB-ID

Zitieren

Meisinger-Henschel C, Schmidt M, Lukassen S, et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. JOURNAL OF GENERAL VIROLOGY. 2007;88(12):3249-3259.
Meisinger-Henschel, C., Schmidt, M., Lukassen, S., Linke, B., Krause, L., Konietzny, S., Goesmann, A., et al. (2007). Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. JOURNAL OF GENERAL VIROLOGY, 88(12), 3249-3259. doi:10.1099/vir.0.83156-0
Meisinger-Henschel, C., Schmidt, M., Lukassen, S., Linke, B., Krause, L., Konietzny, S., Goesmann, A., Howley, P., Chaplin, P., Suter, M., et al. (2007). Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. JOURNAL OF GENERAL VIROLOGY 88, 3249-3259.
Meisinger-Henschel, C., et al., 2007. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. JOURNAL OF GENERAL VIROLOGY, 88(12), p 3249-3259.
C. Meisinger-Henschel, et al., “Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara”, JOURNAL OF GENERAL VIROLOGY, vol. 88, 2007, pp. 3249-3259.
Meisinger-Henschel, C., Schmidt, M., Lukassen, S., Linke, B., Krause, L., Konietzny, S., Goesmann, A., Howley, P., Chaplin, P., Suter, M., Hausmann, J.: Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. JOURNAL OF GENERAL VIROLOGY. 88, 3249-3259 (2007).
Meisinger-Henschel, Christine, Schmidt, Michaela, Lukassen, Susanne, Linke, Burkhard, Krause, Lutz, Konietzny, Sebastian, Goesmann, Alexander, Howley, Paul, Chaplin, Paul, Suter, Mark, and Hausmann, Juergen. “Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara”. JOURNAL OF GENERAL VIROLOGY 88.12 (2007): 3249-3259.

40 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Characterization of indels in poxvirus genomes.
Coulson D, Upton C., Virus Genes 42(2), 2011
PMID: 21153876
Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.
Rehm KE, Roper RL., Vaccine 29(17), 2011
PMID: 21352940
Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.
Dimier J, Ferrier-Rembert A, Pradeau-Aubreton K, Hebben M, Spehner D, Favier AL, Gratier D, Garin D, Crance JM, Drillien R., J Virol 85(10), 2011
PMID: 21367889
The strategic use of novel smallpox vaccines in the post-eradication world.
Golden JW, Hooper JW., Expert Rev Vaccines 10(7), 2011
PMID: 21806397
Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.
Walsh SR, Dolin R., Expert Rev Vaccines 10(8), 2011
PMID: 21854314
Innate immune recognition of poxviral vaccine vectors.
Lousberg EL, Diener KR, Brown MP, Hayball JD., Expert Rev Vaccines 10(10), 2011
PMID: 21988308
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.
von Krempelhuber A, Vollmar J, Pokorny R, Rapp P, Wulff N, Petzold B, Handley A, Mateo L, Siersbol H, Kollaritsch H, Chaplin P., Vaccine 28(5), 2010
PMID: 19944151
Mutations in modified virus Ankara protein 183 render it a non-functional counterpart of B14, an inhibitor of nuclear factor kappaB activation.
McCoy LE, Fahy AS, Chen RA, Smith GL., J Gen Virol 91(pt 9), 2010
PMID: 20444990
Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.
Meisinger-Henschel C, Späth M, Lukassen S, Wolferstätter M, Kachelriess H, Baur K, Dirmeier U, Wagner M, Chaplin P, Suter M, Hausmann J., J Virol 84(19), 2010
PMID: 20668072
Interaction of orthopoxviruses with the cellular ubiquitin-ligase system.
Shchelkunov SN., Virus Genes 41(3), 2010
PMID: 20703935
Genome comparison of a nonpathogenic myxoma virus field strain with its ancestor, the virulent Lausanne strain.
Morales M, Ramírez MA, Cano MJ, Párraga M, Castilla J, Pérez-Ordoyo LI, Torres JM, Bárcena J., J Virol 83(5), 2009
PMID: 19091868
Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.
Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, Sandström E, Wahren B., Vaccine 27(33), 2009
PMID: 19450644
Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain.
Suter M, Meisinger-Henschel C, Tzatzaris M, Hülsemann V, Lukassen S, Wulff NH, Hausmann J, Howley P, Chaplin P., Vaccine 27(52), 2009
PMID: 19539582
Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.
Garza NL, Hatkin JM, Livingston V, Nichols DK, Chaplin PJ, Volkmann A, Fisher D, Nalca A., Vaccine 27(40), 2009
PMID: 19632316
Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection.
Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H, Chaplin P, Suter M, O'Keeffe M, Hochrein H., J Clin Invest 118(5), 2008
PMID: 18398511

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 18024893
PubMed | Europe PMC

Suchen in

Google Scholar